| Charles Bg Knight, MD | |
|
2314 Nw Kings Blvd # A, Corvallis, OR 97330-3925 | |
| (541) 758-5047 | |
| (541) 758-3713 |
| Full Name | Charles Bg Knight |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 23 Years |
| Location | 2314 Nw Kings Blvd # A, Corvallis, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194869388 | NPI | - | NPPES |
| 274236 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD27407 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| William W Backus Hospital | Norwich, CT | Hospital |
| The Hospital Of Central Connecticut | New britain, CT | Hospital |
| Midstate Medical Center | Meriden, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Diagnostic Imaging Services Of Ct Llc | 3577465111 | 14 |
| Meriden Imaging Center Inc | 4385683556 | 49 |
| Midstate Radiology Associates, Llc | 4880593565 | 73 |
News Archive
In patients with metastatic renal cell carcinoma, the biomarker serum lactate dehydrogenase is both prognostic for survival and predictive for the survival benefit conferred by the TORC1 inhibitor temsirolimus, research shows.
InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.
A new research study reveals RAC1 protein could be a new therapeutic target to study the molecular mechanisms related to the neurodegenerative processes in Parkinson's disease.
ytRx Corporation, a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in the treatment of acute promyelocytic leukemia (APL) in patients failing other treatments.
› Verified 4 days ago
| Entity Name | Midstate Radiology Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578518999 PECOS PAC ID: 4880593565 Enrollment ID: O20031231000543 |
News Archive
In patients with metastatic renal cell carcinoma, the biomarker serum lactate dehydrogenase is both prognostic for survival and predictive for the survival benefit conferred by the TORC1 inhibitor temsirolimus, research shows.
InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.
A new research study reveals RAC1 protein could be a new therapeutic target to study the molecular mechanisms related to the neurodegenerative processes in Parkinson's disease.
ytRx Corporation, a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in the treatment of acute promyelocytic leukemia (APL) in patients failing other treatments.
› Verified 4 days ago
| Entity Name | Diagnostic Imaging Services Of Ct Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093760431 PECOS PAC ID: 3577465111 Enrollment ID: O20040123000288 |
News Archive
In patients with metastatic renal cell carcinoma, the biomarker serum lactate dehydrogenase is both prognostic for survival and predictive for the survival benefit conferred by the TORC1 inhibitor temsirolimus, research shows.
InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.
A new research study reveals RAC1 protein could be a new therapeutic target to study the molecular mechanisms related to the neurodegenerative processes in Parkinson's disease.
ytRx Corporation, a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in the treatment of acute promyelocytic leukemia (APL) in patients failing other treatments.
› Verified 4 days ago
| Entity Name | Meriden Imaging Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508812561 PECOS PAC ID: 4385683556 Enrollment ID: O20050427000621 |
News Archive
In patients with metastatic renal cell carcinoma, the biomarker serum lactate dehydrogenase is both prognostic for survival and predictive for the survival benefit conferred by the TORC1 inhibitor temsirolimus, research shows.
InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.
A new research study reveals RAC1 protein could be a new therapeutic target to study the molecular mechanisms related to the neurodegenerative processes in Parkinson's disease.
ytRx Corporation, a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in the treatment of acute promyelocytic leukemia (APL) in patients failing other treatments.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles Bg Knight, MD Po Box 1418, Corvallis, OR 97339-1418 Ph: (541) 758-5047 | Charles Bg Knight, MD 2314 Nw Kings Blvd # A, Corvallis, OR 97330-3925 Ph: (541) 758-5047 |
News Archive
In patients with metastatic renal cell carcinoma, the biomarker serum lactate dehydrogenase is both prognostic for survival and predictive for the survival benefit conferred by the TORC1 inhibitor temsirolimus, research shows.
InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.
A new research study reveals RAC1 protein could be a new therapeutic target to study the molecular mechanisms related to the neurodegenerative processes in Parkinson's disease.
ytRx Corporation, a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in the treatment of acute promyelocytic leukemia (APL) in patients failing other treatments.
› Verified 4 days ago
Mr. James C Dunn, Radiology Medicare: Accepting Medicare Assignments Practice Location: 2314 Nw Kings Blvd # A, Corvallis, OR 97330 Phone: 541-758-5047 Fax: 541-758-3713 | |
Bruce E Frey, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 501 Nw Elks Dr, Corvallis, OR 97330 Phone: 541-768-5220 Fax: 541-768-5303 | |
Mary M Austin-seymour, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 501 Nw Elks Dr, Corvallis, OR 97330 Phone: 541-768-5220 | |
Dr. Kate Taylor Doyle, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1121 Sw Sunset Dr, Corvallis, OR 97333 Phone: 952-595-1100 Fax: 952-942-3361 | |
Leslie Ann Arpin, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2314 Nw Kings Blvd Ste A, Corvallis, OR 97330 Phone: 541-758-5047 Fax: 541-758-3713 | |
Jefferson A Hamlin, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2314 Nw Kings Blvd, Corvallis, OR 97330 Phone: 541-758-5047 Fax: 541-758-3713 |